FDA requests additional trial of Cinryze in acute indication

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Oral RNA splicing modulator has gone into a Phase II/III trial

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.